In the following article1 the authors would like to add the research funding from the Leverhulme Trust to the acknowledgements section on page 258. The updated acknowledgement section with the correct funding information is shown below.
Acknowledgements
We thank Dimitris Kioussis (MRC/National Institute for Medical Research) for the NOD‐hCD2‐GFP mice. We thank L. Wright, A. Dinsdale, L. Broome, Mr Nigel Miller and Y.K. Sawyer (University of Cambridge) for excellent technical support, and Nick Holmes (University of Cambridge) for helpful discussions. This work was funded by grants from the National Centre for the Replacement, Refinement and Reduction of Animals in research (NC3Rs) (NC/M001083/1) (MW), Diabetes UK (BDA 13/0004785) (AC), Diabetes Research and Wellness (SCA/OF/12/13) (AC), European Research Council 7th Frame Programme (health‐f5‐2009‐241883) (AC and HW), Britain Israel Research and Academic Exchange Partnership (BIRAX) (02BX12ACYD) (AC), The Leverhulme Trust (EM‐2015‐030) (AC), ERC advanced investigator grant 339402 (HW) and pump priming funding from the Cambridge University Isaac Newton trust.
Reference
- 1. Wallberg M, Recino A, Phillips J, Howie D, Vienne M, Paluch C et al Anti‐CD3 treatment up‐regulates programmed cell death protein‐1 expression on activated effector T cells and severely impairs their inflammatory capacity. Immunology 2017; 151:248–60. [DOI] [PMC free article] [PubMed] [Google Scholar]